Poseida Therapeutics, Inc.

PSTX

US73730P1084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-09 pm EDT			5-day change	1st Jan Change
2.97 ^USD	0.00%		-1.66%	-11.61%

Jul. 01	Poseida Therapeutics, Inc.(NasdaqGS:PSTX) added to Russell Microcap Growth Index	CI
Jul. 01	Poseida Therapeutics, Inc.(NasdaqGS:PSTX) added to Russell 3000 Growth Index	CI

Poseida Therapeutics, Inc.(NasdaqGS:PSTX) added to Russell Microcap Growth Index

July 30, 2024

Latest news about Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.(NasdaqGS:PSTX) added to Russell Microcap Growth Index	Jun. 30	CI
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) added to Russell 3000 Growth Index	Jun. 30	CI
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) added to Russell 3000E Growth Index	Jun. 30	CI
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) added to Russell 2000 Growth Index	Jun. 30	CI
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) added to Russell 2500 Growth Index	Jun. 30	CI
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises	May. 14	MT
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M	May. 14	MT
Poseida Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	May. 02	MT
Malin Corp investee signs agreement with Astellas Pharma	May. 01	AN
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences	May. 01	DJ
Poseida Therapeutics, Inc. and Xyphos Biosciences, Inc. Enter into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	May. 01	CI
Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma	Apr. 08	CI
Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer	Mar. 25	MT
Poseida Therapeutics, Inc Appoints Syed Rizvi as Chief Medical Officer Effective April 1, 2024	Mar. 25	CI
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q4 Revenue $25M	Mar. 07	MT
Poseida Therapeutics, Inc. Announces Executive Changes	Mar. 07	CI
Poseida Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $10 From $8, Maintains Overweight Rating	Dec. 11	MT
Poseida Therapeutics Reports Positive Results of Phase 1 Blood Cancer Treatment Trial	Dec. 11	MT
Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment	Dec. 11	DJ
HC Wainwright Adjusts Price Target on Poseida Therapeutics to $20 From $15, Keeps Buy Rating	Dec. 11	MT

Chart Poseida Therapeutics, Inc.

Duration

Period

More charts

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Poseida Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.97 USD

Average target price

14 USD

Spread / Average Target

+371.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
POSEIDA THERAPEUTICS, INC.	-11.61%	288M
VERTEX PHARMACEUTICALS INCORPORATED	+19.44%	125B
REGENERON PHARMACEUTICALS, INC.	+20.01%	114B
ARGENX SE	+23.09%	26.73B
BIONTECH SE	-23.72%	19.43B
GENMAB A/S	-17.66%	16.22B
BEIGENE, LTD.	-19.87%	15.33B
SAREPTA THERAPEUTICS, INC.	+55.81%	14.2B
NEUROCRINE BIOSCIENCES, INC.	+8.76%	14.42B
WUXI APPTEC CO., LTD.	-48.79%	14.33B

Bio Therapeutic Drugs